Estrella Immunopharma (Estrella Immunopharma) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Estrella Immunopharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Estrella Immunopharma's long-term debt to total assets ratio declined from Dec. 2022 (0.01) to Mar. 2024 (0.00). It may suggest that Estrella Immunopharma is progressively becoming less dependent on debt to grow their business.

Estrella Immunopharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Estrella Immunopharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma LT-Debt-to-Total-Asset Chart

Estrella Immunopharma Annual Data

Trend

Jun21

LT-Debt-to-Total-Asset

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					0.01	-	-	-	-

Estrella Immunopharma LT-Debt-to-Total-Asset Calculation

Estrella Immunopharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2021 is calculated as

LT Debt to Total Assets (A: Jun. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2021 )	/	Total Assets (A: Jun. 2021 )
	=	0	/	0
	=

Estrella Immunopharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0	/	8.633
	=

Estrella Immunopharma (NAS:ESLAW) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Estrella Immunopharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ESLA:USA

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines